Drug intelligence / Profile preview

perindopril + indapamide + amlodipine

Development stage
Phase 4
Lead developer
Servier
Modality
Small Molecules
Administration
Oral
01

Overview

**Perindopril + indapamide + amlodipine** is an oral, single-pill fixed-dose antihypertensive combination containing an angiotensin-converting enzyme inhibitor, a thiazide-like diuretic, and a dihydropyridine calcium-channel blocker. Perindopril is converted to perindoprilat, which inhibits angiotensin-converting enzyme and reduces angiotensin II formation; indapamide promotes renal sodium and chloride excretion; and amlodipine inhibits L-type calcium channels in vascular smooth muscle to cause vasodilation. The combination is used for essential hypertension, particularly as substitution therapy for patients already controlled on the corresponding component doses. Servier developed the reference product Triplixam, also designated S06593; generic fixed-dose products include Krka's Co-Amlessa and Darnitsa's Perindopres Trio. ([ndf.gov.sg](https://www.ndf.gov.sg/about-drugs/product-information/sin15013p/))

Brand names
AmlewelCo-AmlessaCo-DalnevaPeramindPerindopres TrioTonandaTriplixamViacorlix
Other names
amlodipine + indapamide + perindoprilamlodipine/indapamide/perindoprilperindopril + indapamide + amlodipineperindopril arginine + indapamide + amlodipineperindopril/indapamide/amlodipineperindopril tert-butylamine + indapamide + amlodipine
02

Targets

ACE (Angiotensin Converting Enzyme)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on perindopril + indapamide + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on perindopril + indapamide + amlodipine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call